



## KISUNLA (donanemab-azbt) ORDER FORM

P: 240.200.4464 F: 240.892.3005

**PATIENT INFORMATION:** Fax completed form, insurance information, and clinical documentation to 240.892.3005

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Phone: \_\_\_\_\_

Patient Status: ☐ New to Therapy ☐ Continuing Therapy Next Treatment Date: \_\_\_\_\_

### MEDICAL INFORMATION

Patient Weight: \_\_\_\_\_ lbs./kg. (required) Allergies: \_\_\_\_\_

#### Diagnosis:

- ☐ Alzheimer's Disease with Early Onset (ICD-10: G30.0)
- ☐ Other: \_\_\_\_\_ ICD-10 Code: \_\_\_\_\_
- ☐ Mild Cognitive Impairment (ICD-10: G31.84)
- ☐ Encounter for clinical registry program (ICD-10: Z00.6) \*\*MEDICARE REQUIRED\*

### THERAPY ORDER

**KISUNLA:** 350 mg IV for 1<sup>st</sup> infusion, 700 mg IV for 2<sup>nd</sup> infusion, 1050 mg IV for 3<sup>rd</sup> infusion, then 1400 mg IV every four weeks

- MRIs should be performed at baseline & prior to the 2<sup>nd</sup>, 3<sup>rd</sup>, 4<sup>th</sup>, and 7<sup>th</sup> infusions
- HOLD INFUSION IF MRI IS NOT PERFORMED AT INDICATED INTERVAL

### ADDITIONAL REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVAL

- ☐ Patient enrolled in the CMS National Patient Registry (Medicare and Medicare Advantage required)  
Issue number: \_\_\_\_\_ Date of registry enrollment: \_\_\_\_\_
- ☐ Provide a copy of the CMS national patient registry confirmation
- ☐ Confirmed presence of amyloid pathology. Attach results: Amyloid PET scan OR +CSF (cerebrospinal fluid)
- ☐ MRI of the brain (within 1 year) – attach results
- ☐ Cognitive assessment scores (list all available, attach results):
  - ☐ MMSE: Score \_\_\_\_\_ Date of assessment \_\_\_\_\_
  - ☐ MoCA: Score \_\_\_\_\_ Date of assessment \_\_\_\_\_

Please provide the patient's demographic information, insurance information, medication list, and clinical notes. Active Infusions will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and assist them in enrolling in any available co-pay assistance programs as needed/applicable. Thank you for the referral.

### PROVIDER INFORMATION

Provider Name: \_\_\_\_\_ Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Provider NPI: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_

Contact Person: \_\_\_\_\_

ACTIVEINFUSIONS.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.